Clinical Trial Update: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update comparing pharmacokinetics and pharmacodynamics of a proposed insulin aspart biosimilar/interchangeable (I004) to NovoLog after single-do…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• I004 (insulin aspart biosimilar/interchangeable)
• NovoLog (insulin aspart)

Snippet

Sponsor: Amphastar Pharmaceuticals, Inc. | Conditions: Pharmacokinetics, Pharmacodynamics | Phase 2, Phase 3 | Status: COMPLETED